Novartis has acquired a majority of shares in Swiss pharmaceutical maker Speedel Holding AG. It plans to acquire the remaining shares of Speedel through a mandatory public tender offer.
Speedel and Novartis jointly developed the high blood pressure drug Tekturna, which is known as Rasilez outside of the United States.
Speedel and Novartis jointly developed the high blood pressure drug Tekturna, which is known as Rasilez outside of the United States.
No comments:
Post a Comment